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Abstract
Insulin-like growth factor-1 (IGF-1) plays a critical role in the development of the growing skeleton by establishing both
longitudinal and transverse bone accrual. IGF-1 has also been implicated in the maintenance of bone mass during late
adulthood and aging, as decreases in serum IGF-1 levels appear to correlate with decreases in bone mineral density (BMD).
Although informative, mouse models to date have been unable to separate the temporal effects of IGF-1 depletion on
skeletal development. To address this problem, we performed a skeletal characterization of the inducible LID mouse (iLID),
in which serum IGF-1 levels are depleted at selected ages. We found that depletion of serum IGF-1 in male iLID mice prior to
adulthood (4 weeks) decreased trabecular bone architecture and significantly reduced transverse cortical bone properties
(Ct.Ar, Ct.Th) by 16 weeks (adulthood). Likewise, depletion of serum IGF-1 in iLID males at 8 weeks of age, resulted in
significantly reduced transverse cortical bone properties (Ct.Ar, Ct.Th) by 32 weeks (late adulthood), but had no effect on
trabecular bone architecture. In contrast, depletion of serum IGF-1 after peak bone acquisition (at 16 weeks) resulted in
enhancement of trabecular bone architecture, but no significant changes in cortical bone properties by 32 weeks as
compared to controls. These results indicate that while serum IGF-1 is essential for bone accrual during the postnatal
growth phase, depletion of IGF-1 after peak bone acquisition (16 weeks) is compartment-specific and does not have a
detrimental effect on cortical bone mass in the older adult mouse.
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Introduction
Hormonalregulationthroughoutgrowthandadulthoodisknown
to affect skeletal strength. The interplay between hormones and
geneticfactorsaccountsforsignificantvariabilityinadultBMD,bone
quality,andthekineticsofboneaccrualduringgrowthandboneloss
during aging. IGF-1, which acts in an endocrine and autocrine/
paracrine manner, is one hormone implicated in the establishment
and maintenance of bone integrity. At the cellular level, numerous
in vitro and in vivo studies demonstrated that IGF-1 can affect
osteoblast growth and differentiation [1], induce type I collagen
expression [2] and inhibit type I collagen degradation in differen-
tiated fetal rat osteoblasts [3,4]. Further, IGF-1 plays an important
role in cell survival [5,6], promotes the formation of osteoclast-like
cells from mononuclear precursors and can subsequently stimulate
the resorptive activity of osteoclasts [7,8]. Thus, IGF-1 plays a
fundamental role in coordinating the cellular processes of bone
formation (apposition) and bone removal (resorption).
Serum IGF-1, which is produced largely by the liver, contributes
to the overall skeletal pool of IGF-1. During puberty, in both
humans and mice, linear growth and bone formation are associated
withariseinserumandskeletalIGF-1.Inmice,a rapidbodyweight
gain occurs from birth up to 4 weeks of age [9,10]. During this
period, liver IGF-1 gene expression is activated and rises to adult
levels [11]. Somatic growth during this early growth phase is
affected by global IGF-1 gene deficiency. For example, IGF-1 null
mice exhibit a 35% growth retardation at birth, which increases to
60% by 3 weeks of age [12]. Thus, IGF-1 is crucial in promoting
bone growth during the early growth phase (1–28 days). Early bone
growth plays a critical role in defining adult skeletal integrity
because during this time ,80–90% of adult femoral total area
(Tt.Ar) is established [9], but the later growth phase (4–16 weeks) is
also important as gains in the amount of cortical bone tissue area
(Ct.Ar) increase significantly through the addition of bone on both
the outer (perisoteal) and inner (endosteal) surfaces [9,13,14] and
small gains in longitudinal bone growth exists since the femoral
growthplatedoesnotcloseaftersexualmaturation inmiceasitdoes
in humans. These ontogenic changes in bone size and amount are
clearly dependent on serum IGF-1 levels as liver IGF-1 deficient
(LID) mice, with75% reductions in serum IGF-1from birth, exhibit
only ,6% decreases in bone length but significant reductions
(,30%) in bone mineral density (BMD), Tt.Ar, and Ct.Ar by the
middle of the late growth phase (8 weeks) [15].
In contrast to our understanding of growth and development, the
contribution of serum IGF-1 to skeletal integrity during adulthood
remains unclear. In order to clarify the relationship between serum
IGF-1 levels and skeletal structure in adulthood (after 16 weeks), the
temporal variation in serum IGF-1 must be specifically addressed.
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e14762Given that ourLIDmousemodel exhibits a constitutive serum IGF-
1 deficiency (from birth) we could not rule out an accumulating
effect of IGF-1 on bone development in these animals. To quantify
the effects of IGF-1 during defined growth phases, we developed an
inducible liver IGF-1 deficient mouse model (iLID) that allows us to
deplete circulating IGF-1 at specific stages of mouse development.
The iLID model is based on the Cre/loxP system whereby the Cre
recombinase is expressed specifically in the liver under the anti-
trypsin 1a promoter, and can be induced by a single tamoxifen
injection that does not otherwise affect the skeleton. This model
permits us to dissect the temporal contribution of circulating IGF-1
and contrast the early and later effects of IGF-1 on skeletal
acquisition, maintenance, and micro-architecture.
Materials and Methods
Animals
The iLID model (C57BL/6 backgruond) has been described
previously [16]. Briefly, iLID was created using the Cre-loxP
system and crossing mice with floxed exon 4 of the IGF-1 gene
with transgenic mice expressing tamoxifen-inducible Cre-recom-
binase under the trypsin-1a promoter. In this model, iLID mice
(which are homozygous for the floxed IGF-1 and carry the Cre-
recombinase transgene) exhibit normal levels of IGF-1 in serum.
Upon tamoxifen injection, an igf-1 gene recombination occurs
specifically in hepatocytes, leading to ,60% reductions in serum
IGF-1 levels. Control mice are homozygous for the floxed IGF-1
allele but do not carry the Cre-recombinase and therefore do not
recombine the igf-1 gene in response to tamoxifen injection. Male
mice used in this study were given unrestricted access to water and
food, and housed to a maximum of 5 per cage under a 12 hours
light:dark cycle. Animal care and maintenance were provided
through the Mount Sinai School of Medicine AAALAC
Accredited Animal Facility. All procedures were approved by
the Institutional Animal Care and Use Committee of the Mount
Sinai School of Medicine (protocol number 06-1061).
Validation of the iLID Model
As this investigation required the use of tamoxifen to induce
Cre-recombinase-mediated gene recombination in liver, we
Figure 1. Validation of the iLID model. (A) Liver expression of IGF-1 in control mice (mean 6 SE) is not altered following 0.3 mg tamoxifen
injection. Control mice at 4, 8, 12, 16 and 32 weeks of age were injected with 0.3 mg tamoxifen and livers were dissected four weeks later for gene
expression analysis using real time PCR (n=3 per group). Control and ‘‘constitutive’’ LID mice were used as positive control for the assay. Cycle
number was corrected to b-actin and levels related to vehicle control, which was set as 1. (B) Mean serum IGF-1 levels in control mice (6 SE) injected
with 0.3 mg of tamoxifen (+) at 4 or 8 weeks were not altered compared to vehicle treated controls (2) at 8 or 16 weeks, respectively. (C) Mean serum
GH levels in control mice (6 SE) injected with 0.3 mg of tamoxifen (+) at 4 or 8 weeks were not altered compared to vehicle treated controls (2)a t8
or 16 weeks, respectively. Sera from triple knockout of LID/acid labile subunit KO/IGFBP-3KO (LAB) mice, which have high serum GH levels [24], served
as a positive control. (D) BV/TV (bone volume/total volume) from micro-CT analysis of control mice injected with vehicle (2) or 0.3 mg tamoxifen (+)
at 4, 8, and 12 weeks of age and then analyzed at 8, 12, and 16 weeks, respectively. Trabecular bone was analyzed at the femoral distal metaphysis
(n=6 per group). No significant differences were found between vehicle and 0.3 mg tamoxifen injected mice.
doi:10.1371/journal.pone.0014762.g001
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reduce serum IGF-1 levels by at least 50% in the iLID mice
without affecting bone remodeling per se and 2) not affect
circulating IGF-1 levels in floxed controls. The first part of this
validation has been published previously. Tamoxifen (Sigma
Aldrich, St. Louis, MO, USA) was dissolved in seed oil with
10% ethanol at a concentration of 3 mg/ml, sonicated for 30
minutes and injected intraperitoneally to both iLID and control
mice at the indicated time points. We examined a dose response
effect of tamoxifen on serum IGF-1 levels as well as on igf-1 gene
expression in liver [16]. The minimal effective dose of tamoxifen in
the adult mouse was a single injection of 0.3 mg of tamoxifen.
Using this dose we were able to decrease serum IGF-1 by 60% in
the iLID compared to vehicle treated control (seed oil). We also
verified the time course of serum IGF-1 decrease and revealed that
at ,18 hours after tamoxifen injection both serum IGF-1 levels
and liver IGF-1 mRNA levels were decreased [16].
Serum Hormones
Serum was obtained from blood samples after mandibular
bleeding in the fed state. Serum levels of IGF-1 and GH were
determined using commercial radio-immuno assays as described
previously [15,17,18].
Bone Morphology and Microarchitecture
Diaphyseal and distal metaphyseal regions of left femora were
analyzed using micro-computed tomography (micro-CT). A three-
dimensional micro-CT image of the entire femur was obtained
using an eXplore Locus SP micro-CT system (GE Healthcare,
London, Ontario, CA), which was engineered to minimize beam-
hardening and to produce field flatness through the use of x-ray
filters and an equilibration bath. Scans were performed at 8.7 mm
voxel resolution and bone was delineated from non-bone using a
standard global thresholding algorithm. From the reconstructed
micro-CT images, a 2 mm region of the mid-diaphysis (cortical
bone) beginning immediately distal to the third trochanter was
examined for total cross-sectional bone area (Tt.Ar), cross-
sectional marrow area (Ma.Ar), cortical bone (tissue) area (Ct.Ar),
polar moment of inertia (Jo), cortical thickness (Ct.Th). Relative
cortical area (RCA) was defined as Ct.Ar/Tt.Ar and represented
the relative amount of bone tissue packed into a give bone area.
From the reconstructed images of the distal metaphysis, a 2 mm
region (trabecular bone) immediately proximal to the growth plate
Figure 2. Experimental design, gene expression and serum levels for control and iLID mice. A) Schematic representation of the
experimental design. (B) igf-1 gene expression in liver in control and iLID mice injected with tamoxifen at different ages (C) Mean serum IGF-1 levels
(6 s.d) in control (n=6) and iLID (n=6 each) before (4 weeks) and after (16 weeks) injection of 0.3 mg of tamoxifen at 4 weeks. Serum IGF-1 levels in
iLID mice are statistically different from control mice as expected (ANOVA, p,0.05). (D) Serum GH levels in control (n=8) and iLID mic (n=10) after
depletion of serum IGF-1 by tamoxifen injection.
doi:10.1371/journal.pone.0014762.g002
Figure 3. Body weight and length data for control and iLID
mice. (A) Mean body weight and body length (6 SE) of control (n=6)
and iLID (n=6) mice at 16 weeks after injection of 0.3 mg of tamoxifen
at 4 weeks. (B) Body weights and body lengths (6 s.d) for 32 week
control and iLID after injection of tamoxifen at either 8 or 16 weeks of
age.
doi:10.1371/journal.pone.0014762.g003
Table 1. Mean cortical and trabecular bone traits values (6
s.d) obtained from micro-CT measurements of male femora
from control (n=6) and iLID mice (n=6) at 16 weeks of age
after injection with tamoxifen at 4 weeks.
Cortical Bone Traits Control 4-16 iLID 4-16
Ct.Ar (mm
2) 0.93 6 0.14 0.77 6 0.05*
Tt.Ar (mm
2) 1.90 6 0.27 1.72 6 0.14
Ma.Ar (mm
2) 0.97 6 0.19 0.94 6 0.10
Jo (mm
4) 0.45 6 0.11 0.35 6 0.05
Ct.Th (mm) 0.20 6 0.03 0.17 6 0.01*
RCA 0.49 6 0.05 0.45 6 0.02
TMD (mg/cc) 1217 6 31 1184 6 49
Trabecular Bone Traits Control 4-16 iLID 4-16
BMD (mg/cc) 104 6 34 105 6 13
BV/TV (%) 19.4 6 4.5 22.5 6 1.6
TMD (mg/cc) 525 6 61 464 6 38
Tb.Th (mm) 0.054 6 0.004 0.050 6 0.001*
Tb.N (mm
-1) 3.59 6 0.59 4.50 6 0.35*
Tb.Sp (mm) 0.23 6 0.05 0.17 6 0.02*
*Significantly different from control (ANOVA, p,0.05).
doi:10.1371/journal.pone.0014762.t001
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volume (BV/TV), trabecular number (Tb.N), trabecular thickness
(Tb.Th), and trabecular spacing (Tb.Sp). BMD was calculated as
the ratio of bone mineral content (BMC, mg) to the total volume of
distal metaphysis analyzed after removing (masking) marrow space
grayscale variability. In addition, tissue mineral density (TMD)
values were obtained which represent the amount of mineral in a
given bone tissue as compared to a hydroxyapatite standard.
Histology
Animals were injected with calcein (20 mg/kg) twice before
sacrifice. Isolated femora were cleaned of soft tissue, fixed in 10%
buffered formalin and embedded in poly-methylmethacrylate
(PMMA). For trabecular analysis, longitudinal sections (5 mm
thick) were cut at the 50% coronal plane using a Leica 2265
microtome, deplasticized and stained with Goldner’s Trichrome
stain for static measurements based on morphology (e.g.,
osteoblast and osteoclast number). Additional sections were cut
at 10 mm for the dynamic (fluorescent) measurements. For each
sample, a region of interest was defined 250 mm distal to the
growth plate and extending 1 mm downward (thereby avoiding
the primary spongiosa) through the metaphysis of the femur.
Standard bone histomorphometry was performed as described
previously [19] using Bioquant Image Analysis software (R & M
Biometrics, Nashville, TN). For cortical analysis, 200 mm sections
were cut at the mid-diaphysis using a low-speed diamond saw
(Buehler, Inc., Lake Bluff, IL, USA). Sections were mounted on
glass sides, polished to ,50 mm, and analyzed for dynamic
(fluorescent) measurements using OsteoMeasure (Osteometrics,
Atlanta, GA, USA) as described previously [19].
Gene Expression
Total RNA was extracted from liver samples using TRIzol
reagent according to the manufacturer’s instructions (Invitrogen
Corp., Carlsbad, California, USA). RNA integrity was verified
using Bioanalyzer (Agilent Technologies 2100 Bioanalyzer-Bio
Sizing, Version A.02.12 SI292). One mg of RNA was reverse-
transcribed to cDNA using oligo(dT) primers with a RT-PCR kit
according to the manufacturer’s instructions (Invitrogen). Quan-
titative RT-PCR was performed with the QuantiTect
TM SYBR
H
green PCR kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions in ABI PRISM 7900HT sequence
detection systems (Applied Biosystems, Foster City, CA USA).
Each transcript in each sample was assayed three times and the
fold change ratios between experimental and control samples were
calculated relative to b-actin.
Statistics
Statistical differences between mean trait values of iLID mice and
control mice were assessed using one-way ANOVA and Bonferroni
post-hoc tests (p,0.05, Statistica 6.0, Statsoft, Tulsa, OK, USA).
Results
Validation of the iLID model for Skeletal Studies
To address whether injection of 0.3 mg of tamoxifen affected
liver igf-1 gene expression in wild-type mice, we injected 0.3 mg of
Figure 4. Micro-CT images of control and iLID mice indicating
differences in cortical and trabecular bone accrual. (A) Mice
injected with tamoxifen at 4 weeks and sacrificed at 16 weeks. (B) Mice
injected with tamoxifen at 8 weeks and sacrificed at 32 weeks. (C) Mice
injected with tamoxifen at 16 weeks and sacrificed at 32 weeks.
doi:10.1371/journal.pone.0014762.g004
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IGF-1 mRNA levels by real time PCR. No differences in igf-1 gene
expression were detected between tamoxifen and vehicle-injected
control mice at any age (4, 8, 12, 20 and 32 weeks) (Figure 1A).
Serum IGF-1 levels following a 0.3 mg tamoxifen injection were
evaluated using radio-immunoassay and revealed no differences
between tamoxifen and vehicle injected control mice (Figure 1B).
In the LID model we showed that the low levels of serum IGF-1
were not adequate to inhibit pituitary GH secretion. As seen in
Figure 1C, serum GH levels were not affected by 0.3 mg
tamoxifen injection in control mice. To quantify the effects of
0.3 mg of tamoxifen on the trabecular architecture, we analyzed
33 femurs of male control mice at different ages. Our results
revealed no differences in distal femoral BV/TV in control mice
injected once with tamoxifen at 4 weeks and then analyzed at 8
weeks, nor any differences in animals injected at 8 weeks and
analyzed at 12 or 16 weeks (Figure 1D).
Depletion of serum IGF-1 levels during puberty leads to
reductions in cortical and trabecular bone acquisition by
adulthood
As a result of the aforementioned experiments, a single
0.3 mg/mouse injection of tamoxifen was chosen as an
appropriate dose to study the effect of temporal IGF-1 deletion
on the skeletal development of growing mice. Using the iLID
model only one injection of tamoxifen is required since
hepatocytes (in which gene recombination is induced) have low
turnover rate and the genetic recombination is persistent for at
least 16 weeks. Our experimental design is presented in figure 2A;
male control and iLID mice were injected once with tamoxifen
(0.3 mg/mouse) at 4, 8 or 16 weeks of age and were followed
until peak bone acquisition, at 16 (based on prior studies of
cortical bone growth in C57BL/6 mice [9,13]) or at 32 weeks of
age. A single injection of tamoxifen resulted in decreased igf-1
gene expression in liver of all iLID groups (Figure 2B) and
consequent reductions in serum IGF-1 levels, which persisted
until sacrifice at 16 or 32 weeks of age in iLID mice (Figure 2C).
The reduction in serum IGF-1 levels in the iLID mice were
accompanied by elevations in serum GH levels, which were
detectable at the age of sacrifice (Figure 2D).
When depleted of serum IGF-1 at 4 weeks, body weight and
body length of iLID mice did not differ significantly from controls
at 16 weeks of age (Figure 3A). However, 16-week cortical bone,
analyzed at the mid-diaphysis, showed significant reductions in
Ct.Ar and Ct.Th in iLID mice depleted of serum IGF-1 at 4 weeks
of age (Table 1, Figure 4A). Although histomorphometric analysis
of cortical bone did not show significant differences between
control and iLID mice at this age, likely due to the fact that bone
formation slows appreciably by 16 weeks, mean values were all
lower for iLID mice as compared to controls (Table 2). Trabecular
architecture from the femoral distal metaphysis was also quantified
using micro-CT (Table 1, Figure 4A). We found that depletion of
serum IGF-1 beginning at 4 weeks of age resulted in a significant
increase in Tb.N by 16 weeks of age compared to the vehicle
treated group. There was also a concomitant decrease in Tb.Th
and Tb.Sp for both groups.
Depletion of serum IGF-1 levels before and after peak
bone acquisition affects cortical and trabecular bone
architecture differently in the adult mouse
Additional groups of male control and iLID mice were injected
once with tamoxifen (0.3 mg/mouse) at 8 or 16 weeks and were
followed until 32 weeks (post-peak bone acquisition) (Figure 2A) to
determine if a reduction in serum IGF-1 (Figure 2C) during the
late growth phase (8 weeks) and at peak bone acquisition (16
weeks) would have different consequences during the adult growth
phase (after peak bone acquisition). At 32 weeks body weights and
body lengths were identical between iLID and control mice that
had been injected with tamoxifen at 8 weeks (Figure 3B). Micro-
CT data of cortical bone revealed significant reductions in Ct.Ar
and Ct.Th of iLID mice at 32 weeks as compared to controls
(Table 3, Figure 4B). Although histomorphometric analysis of
cortical bone did not show significant differences between control
and iLID mice at this age, likely due to the fact that bone
formation has slowed tremendously by 32 weeks, mean values
were all lower for iLID mice as compared to controls (Table 4).
Trabecular bone architecture was not significantly different
between 8 week injected iLID and control mice at 32 weeks of
age (Table 3). For mice injected at 16 weeks, body weights of iLID
mice also did not differ significantly from controls at 32 weeks
(Figure 3B). Further, micro-CT analysis revealed that temporal
depletion of serum IGF-1 at 16 weeks resulted in no significant
alterations of cortical bone properties at 32 weeks of age (Table 3).
However, we found significant changes in trabecular bone
architecture where BMD, BV/TV, and Tb.N increased and
Tb.Sp decreased in iLID mice (Table 3, Figure 4C). These
findings were supported by histomorphometric data, indicating
significant increases in mineralizing surface (MS) and bone
formation rate (BFR) for iLID mice as compared to controls
(Table 5). To determine if tissue-level expression of IGF-1 or the
IGF-1R was altered in mice injected with tamoxifen at 16 weeks,
we performed immunofluoresence on sections of 32 week cortical
and trabecular bone from control and iLID mice and detected no
differences between iLID and control mice (Figure 5).
Table 2. Mean femoral histomorphometric data (6 s.d) of cortical bone from male control (n=7) and iLID mice (n=9) at 16 weeks
of age after injection with tamoxifen at 4 weeks.
L. Pm MAR BFR/B. Pm # Samples Lacking
(%) (mm/day) (mm/day*100) Double Labels
Periosteal Control 32.4 6 10.2
a 1.3 6 0.2 49.0 6 12.1 2
Surface iLD 24.9 6 10.8
a,b 1.2 6 0.4 35.6 6 20.1
a 2
Endosteal Control 54.1 6 16.7 1.2 6 0.1 69.3 6 23.5 1
Surface iLID 44.7 6 9.8 1.1 6 0.3 50.3 6 15.1 0
aSignificantly different from control endosteal,
bsignificantly different from iLID endosteal (ANOVA, p,0.05).
doi:10.1371/journal.pone.0014762.t002
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In humans, serum GH and IGF-1 decline gradually from ,30
years of age [20,21], while in mice serum IGF-1 levels remain
fairly constant [22]. Mouse models with disrupted genes that
encode components of the GH/IGF axis typically show develop-
mental impairment of the skeletal system, which is carried on to
adulthood [23,24]. Moreover, tissue specific approaches, where
genes of the GH/IGF system were ablated or overexpressed, were
not able to distinguish the skeletal effect of IGF-1 during
development and adulthood phases [25,26]. In sharp contrast,
the iLID model permits both temporal and spatial manipulation of
the igf-1 gene, allowing us to induce igf-1 gene recombination
specifically in the liver at different time points during growth,
adulthood or aging.
In this study we present a novel application of the induced liver
IGF-1 deficiency (iLID) mouse model for skeletal characterization.
Our initial experiments were conducted to validate the iLID
model for skeletal studies. We found that a single intraperitoneal
injection of tamoxifen (0.3 mg) to iLID mice is sufficient to induce
igf-1 gene recombination in the liver and consequently drop serum
IGF-1 levels by ,60%. In control mice, however, this dose of
tamoxifen did not alter igf-1 gene expression in the liver, nor did it
result in reductions in serum IGF-1 levels. Tamoxifen is a selective
estrogen receptor modulator (SERM) that exhibits a potent anti-
estrogen effect on mammary epithelium [27] and a partial
agonistic effect on trabecular bone [28,29,30]. Thus, we assessed
the consequences of tamoxifen injection in vivo on bone
microarchitecture. We found that our selected tamoxifen dose
(i.e., 0.3 mg) did not affect BV/TV in control mice at 4, 8, 16, or
32 weeks of age as no differences were found between tamoxifen
and vehicle injected mice.
Using the iLID model we found that depletion of serum IGF-1
at 4 weeks of age (beginning of late growth phase) did not affect
body weight or body length at 16 weeks. This is in contrast to the
LID mice, which show constitutive reductions in serum IGF-1
from birth and thus significant reductions in body weight
beginning at ,12 weeks [24,31]. We therefore conclude that
maintenance of normal serum IGF-1 levels prior to puberty
(before 4 weeks) enabled iLID mice to maintain body weight and
length values that were identical to adult controls (16 weeks).
Assessment of skeletal architecture showed that depletion of serum
Table 4. Mean femoral histomorphometric data (6 s.d) of cortical bone from male control (n=10) and iLID mice (n=6)at32
weeks of age after injection with tamoxifen at 8 weeks.
L. Pm MAR BFR/B. Pm # Samples Lacking
(%) (mm/day) (mm/day*100) Double Labels
Periosteal Control 39.6 6 8.5 0.7 6 0.2 27.2 6 9.6 0
Surface iLD 32.0 6 18.0 0.5 6 0.1 20.3 6 9.8 1
Endosteal Control 45.5 6 13.1 0.7 6 0.1 31.9 6 12.8 0
Surface iLID 27.5 6 7.7 0.6 6 0.2 17.9 6 8.8 1
No significant differences were found.
doi:10.1371/journal.pone.0014762.t004
Table 3. Mean cortical and trabecular bone traits values (6 s.d) obtained from micro-CT measurements of male femora from
control (n=12) and iLID mice (n=7) at 32 weeks of age after injection with tamoxifen at 8 weeks and male femora from control
(n=14) and iLID mice (n=14) at 32 weeks of age after injection with tamoxifen at 16 weeks.
Cortical Bone Traits Control 8-32 iLID 8-32 Control 16-32 iLID 16-32
Tt.Ar (mm
2) 1.87 6 0.22 1.77 6 0.11 1.93 6 0.13 1.90 6 0.20
Ct.Ar (mm
2) 0.85 6 0.06 0.77 6 0.06* 0.88 6 0.05 0.85 6 0.07
Ma.Ar (mm
2) 1.01 6 0.19 1.01 6 0.08 1.05 6 0.09 1.05 6 0.15
Jo (mm
4) 0.41 6 0.07 0.36 6 0.04 0.44 6 0.05 0.42 6 0.08
Ct.Th (mm) 0.18 6 0.01 0.17 6 0.01* 0.19 6 0.01 0.18 6 0.01
RCA 0.46 6 0.05 0.43 6 0.03 0.46 6 0.02 0.45 6 0.03
TMD (mg/cc) 1330 6 45 1331 6 54 1338 6 30 1317 6 42
Trabecular Bone Traits Control 8-32 iLID 8-32 Control 16-32 iLID 16-32
BMD (mg/cc) 46 6 18 45 6 14 61 6 16 76 6 22*
BV/TV (%) 8.4 6 1.7 11.5 6 3.1 8.4 6 1.7 11.5 6 3.1*
TMD (mg/cc) 584 6 52 588 6 50 708 6 64 654 6 89
Tb.Th (mm) 0.029 6 0.004 0.029 6 0.003 0.034 6 0.004 0.033 6 0.004
Tb.N (mm
-1) 2.66 6 0.98 2.64 6 0.81 2.49 6 0.44 3.48 6 0.96*
Tb.Sp (mm) 0.43 6 0.27 0.38 6 0.12 0.38 6 0.07 0.27 6 0.08*
*Significantly different from tamoxifen injection-matched control (ANOVA, p,0.05).
doi:10.1371/journal.pone.0014762.t003
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of age) resulted in significant reductions in Tb.Th and Tb.Sp while
Tb.N increased. In addition, there was a tendency towards
increased BV/TV in iLID mice. Thus, depletion of IGF-1 during
late growth results in changes to the trabecular architecture by
adulthood. These changes may be due to elevations in GH levels
that are found in iLID mice [24]. iLID mice depleted of IGF-1 at 4
weeks had significant reductions in Ct.Ar and Ct.Th as compared
to control mice highlighting the importance of serum IGF-1
during the pubertal growth period. Given that significant growth is
also achieved after puberty (8 weeks), we predicted that depletion
of serum IGF-1 at 8 weeks should result in a measurable growth
deficit at a later age. In support of this, injection of iLID mice at 8
weeks resulted in significant reductions in cortical bone properties
(Ct.Ar, Ct.Th) by 32 weeks suggesting that reductions in serum
IGF-1 in the middle of the late growth phase (8 weeks) can
influence cortical bone properties in the older adult mouse. These
findings are in agreement with previous findings regarding mouse
development; although the greatest changes in cortical bone
properties are seen before 16 weeks, new bone continues to be
added more slowly well into adulthood [9,13,14]. Thus, although
depletion of serum IGF-1 from birth or early post-natally (before 4
weeks) result in reductions in cortical bone accrual that exist
throughout growth and into adulthood [32], reductions of serum
IGF-1 levels during pubertal growth (late growth phase) are also
Figure 5. Representative immunofluroescene images of cortical and trabecular bone from 32 week control and iLID mice that were
serum IGF-1 depleted at 16 weeks of age. Antibody staining for IGF-1 and the IGF-1R showed no differences when comparing control and iLID
mice.
doi:10.1371/journal.pone.0014762.g005
Table 5. Mean femoral histomorphometric data (6 s.d) of
trabecular bone from male control (n=6) and iLID mice (n=7)
at 32 weeks of age after injection with tamoxifen at 16 weeks.
Control 16-32 iLID 16-32
ES/BS 1.19 6 0.55 1.31 6 0.69
N.Ob/BS (#/mm) 10.74 6 2.81 12.59 6 1.33
N.Oc/BS (#/mm) 0.48 6 0.20 0.42 6 0.21
MS/BS (%) 38.80 6 3.51 66.08 6 8.59*
MAR (mm/day) 0.71 6 0.16 0.86 6 0.16
BFR/BS (mm/day) 0.28 6 0.07 0.57 6 0.11*
*Significantly different from control (ANOVA, p,0.05).
doi:10.1371/journal.pone.0014762.t005
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adulthood.
In the second part of our study we depleted IGF-1 at 16 weeks
and assessed the skeletal response at 32 weeks of age. Mean Ma.Ar
was not different between iLID and control mice at any age
(regardless of the age of tamoxifen injection). In our previous study
with the LID mice we show compensatory decreases in Ma.Ar by
32 weeks [24], likely due to inhibition of periosteal bone
apposition. The absence of Ma.Ar changes in iLID mice suggests
that compensatory marrow infilling occurs when a cumulative
effect of reduced serum IGF-1 is present early post-natally and
during puberty. In contrast to depletion at 4 weeks, depletion of
serum IGF-1 at 16 weeks had no effect on cortical bone
architecture assessed by 32 weeks of age, but did result in
significant increases in trabecular BMD, BV/TV, and Tb.N.
These results imply that serum IGF-1 depletion at maturity (after
establishment of peak bone acquisition), does not affect cortical
skeletal integrity and tissue mineral density (TMD) in the older
adult mouse, but does alter trabecular architecture. Whether this
trabecular enhancement can be maintained during aging (.52
weeks) is unknown. However, given the lack of a cortical bone
phenotype in mice depleted of serum IGF-1 at 16 weeks and
analyzed at 32 weeks, it is possible that the association of serum
IGF-1 with BMD, although noted for peak bone mass in mice
[33], may not hold during adulthood when bone mass gains slow
and bone loss becomes more prevalent. Indeed, the correlations
between serum IGF-1 and BMD noted in several human cohort
studies of older individuals [34,35,36,37], are likely not a direct
cause and effect relationship.
One limitation to this study is that, although serum levels are
reduced in the iLID model, compensatory changes in tissue level
IGF-1 production may result. Robust measures of tissue-level IGF-
1 are not easily obtained as any IGF-1 protein observed may still
be a result of autocrine/paracrine or endocrine production.
Further, such examinations would require knowledge of the
specific time after serum IGF-1 depletion that corresponds to IGF-
1 upregulation. However, we examined IGF-1 and IGF-1R
expression in 32 week control and iLID animals by immunohis-
tochemistry and found no differences. Further, in our iLID mice
up-regulations in tissue IGF-1 are unlikely to be present or, if
present, are insufficient given that impaired cortical skeletal
development was observed by 16 weeks. Thus, we are confident
that changes in tissue-level IGF-1 are not compensating for
reductions in serum IGF-1.
This study and others have shown that heritable differences in
circulating IGF-1 track with bone mass during growth (post-natal
and during puberty) and are most evident during peak bone
acquisition. Such differences may place certain individuals at an
‘‘at-risk starting point’’ for age-related bone loss. Our results of
serum IGF-1-depleted adult mice suggest that reductions of IGF-1
in older adults have less impact on bone mass than reductions in
serum IGF-1 during growth. We suggest that the relationships
observed between IGF-1 and bone mass in the aging human are
likely a ‘‘carry-over’’ from the IGF-1-dependent differences in
bone morphology and composition that are established during
early growth (post-natal to pubertal).
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